Saltos, A. N., Arrowood, C., Beasley, G., Ronald, J., El-Haddad, G., Guerra-Guevara, L., … Ready, N. E. (2023). A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Saltos, Andreas Nicholas, Christy Arrowood, Georgia Beasley, James Ronald, Ghassan El-Haddad, Luiziane Guerra-Guevara, Uzma Khan, et al. “A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Saltos AN, Arrowood C, Beasley G, Ronald J, El-Haddad G, Guerra-Guevara L, et al. A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Saltos, Andreas Nicholas, et al. “A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Saltos AN, Arrowood C, Beasley G, Ronald J, El-Haddad G, Guerra-Guevara L, Khan U, Wolf S, Gu L, Wang XF, Foresman D, Yu X, Cantwell MJ, Antonia SJ, Beg AA, Ready NE. A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2023.